Evidence map›Paper›PMID 42626086›Full record

ArticleFrontiers in cell and developmental biology2026

Integrative transcriptomic and experimental analyses prioritize TPT1 as a PANoptosis-associated candidate molecular marker in sarcopenia.

Shijie Dong, Min Wang, Chen Liang, Peiyu Xu, Ziyi Ye, Jingqing Yao, Zhongquan Tang, Ting Ou, Xiaomin Zhao, Xinyu Dai and 2 more

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shijie Dong *Department of Neurology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Min Wang *Department of General Practice, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chen Liang *Department of Neurology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Peiyu XuDepartment of Neurology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ziyi YeDepartment of Neurology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jingqing YaoDepartment of General Practice, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhongquan TangDepartment of General Practice, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ting OuDepartment of General Practice, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaomin ZhaoDepartment of General Practice, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xinyu DaiDepartment of General Practice, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yuntao LiDepartment of General Practice, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Guozhong JiDepartment of General Practice, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sarcopenia lacks sensitive molecular markers for early detection, and its relationship with integrated inflammatory cell-death programs remains unclear. PANoptosis integrates apoptotic, pyroptotic, and necroptotic signaling and therefore provides a plausible framework for investigating inflammatory-stress remodeling in aging skeletal muscle. Methods: We integrated four bulk-transcriptomic datasets from the Gene Expression Omnibus into a training cohort (66 controls; 37 sarcopenia) and used GSE111016 as an external validation cohort (20 controls; 20 sarcopenia). We intersected differentially expressed genes with a curated PANoptosis-associated gene set and then performed enrichment analysis; least absolute shrinkage and selection operator (LASSO), random forest and extreme gradient boosting (XGBoost) feature selection; nomogram and receiver operating characteristic (ROC) analyses; CIBERSORT immune-cell deconvolution; and single-nucleus RNA sequencing (snRNA-seq) reanalysis. We assessed tumor protein, translationally controlled 1 (TPT1) expression in D-galactose-treated mouse and C2C12 models. Results: Among 608 differentially expressed genes, 47 overlapped with the curated PANoptosis-associated gene set. These genes were enriched in apoptotic signaling; cytokine, nuclear factor kappa B (NF-κB), tumor necrosis factor (TNF), and nucleotide-binding oligomerization domain (NOD)-like receptor pathways; regulated necrosis; extracellular-matrix remodeling; and impaired oxidative phosphorylation. Three machine-learning algorithms converged on neurotrophic receptor tyrosine kinase 1 (NTRK1), TPT1, and TNF receptor-associated protein 1 (TRAP1). TPT1 showed the strongest single-gene discrimination, with areas under the ROC curve of 0.819 (95% confidence interval [CI], 0.737-0.900) in the training cohort and 0.753 (95% CI, 0.598-0.907) in the external cohort. Immune-cell deconvolution linked the candidate genes to estimated mast-cell, plasma-cell, cluster of differentiation 8-positive (CD8 Conclusion: This study prioritizes TPT1 as a candidate molecular marker associated with the bulk-transcriptomic sarcopenia phenotype. The aging-muscle and D-galactose analyses provide biological context but do not establish sarcopenia specificity or causality. Prospective clinical validation and functional perturbation studies are required.

Indexed as

candidate molecular markermachine learningPANoptosissarcopeniasingle-nucleus RNA sequencingskeletal-muscle agingTPT1

Identifiers

PMID42626086
PMCPMC13490725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.